Biologics Safety: Stronger Pharmacovigilance For First-In-Class BLAs Urged In JAMA Report
This article was originally published in The Pink Sheet Daily
Over 23 percent of biologics were subject to post-approval “Dear Doctor” communications or black box warnings during a 12-year period, study finds.
You may also be interested in...
While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.